The c-myc gene is a cellular gene homologous to the transforming gene (v-myc) of avian myelocytomatosis virus (MC29). Its alteration, elevated transcript, or both, have been reported in many malignant hematopoietic cells, their cultured cell lines (4, 7, 10) and in other types of tumors and their lines (1, 6, 8) , thereby being implicated in the genesis of malignant cells. There have been, however, no publications describing alteration of the c-myc gene or the elevation of its transcript in ovarian tumors and their lines. We here report the experimental findings that indicate the amplification of c-myc gene in the human ovarian tumor lines OS-4 and OvCa-1 and findings on an elevated relative amount of the transcript from the c-myc-gene in OS-4.
Human ovarian tumor lines, OS-4, OvCa-1, OCL-1 and OY-1, that had been maintained in nude mice, were used [OCL-1 (11) , and the other tumor lines were the kind gift of Dr. K. Suzumori, Nagoya City University, Japan]. The controls used were HL-60 cells that had c-myc gene amplification and an elevated transcript (4, 10) and apparently normal tissue (supplied by Dr. K. Kuzuya of our center) from an ovary excised from a patient with endometriosis (hereafter called normal tissue). OS-4 at the passage of 20 ("at the passage of" hereafter abbreviated "p"), OCL-1(p42), OY-1(p40), HL-60, and normal tissue thus obtained were used for preparation of DNA and RNA. OS-4(p4), OCL-1(p14), and OvCa-1(p9) were so limited in amounts that each entire sample was used to prepare DNA.
The DNAs prepared were cleaved with EcoRI then given a Southern blot analysis with the rat c-myc sequence as the probe (Fig. 1) . All the samples gave single bands that showed the same electrophoretic mobility [autoradiographic result of OCL-1(p14) not shown]; but the intensities of these bands differed. The DNA fragments on these bands were estimated to be 14 kilobases (kb) long from a comparison of the position of the bands with the positions of bands of the EcoRI-fragments of A-DNA. Densitometry showed that the bands of OS-4(p4), OS-4(p20), OvCa-1(p9) and HL-60 were 5.4-fold, 2.1-fold, 3.6-fold, and 10-fold stronger than the band of normal tissue, respectively; whereas the bands for the rest of the tumor samples were the same as the band for normal tissue. This means that tumors with a higher intensity than normal tissue had a DNA sequence containing the "14 kb" EcoRI fragment amplified as indicated by the higher intensities. Dalla Favera et al. (4) reported that in HL-60 cells the 13 kb DNA sequence delimited with EcoRI-cutting sites (EcoRI segment) containing the complete (functional) c-myc gene was amplified, whereas the other EcoRI segments containing a pseudo c-myc gene or c-mycrelated sequences were not. On comparing their results and our HL-60 results, we inferred, that the "14 kb" EcoRI fragment that we detected corresponds to the "13 kb" EcoRI segment in their report.
To confirm this, we cleaved sample DNAs with EcoRI then with Hind III and analyzed them by Southern blot hybridization using the rat c-myc sequence probe. The cleavage map of the 13 kb EcoRI fragment predicted that our cleavage would produce a 8.2 kb sub-fragment containing the c-myc sequence from the 13 kb EcoRI fragment (3). For our inference to be valid, one band would have to appear in each sample at the position where 8.2 kb DNA fragment would migrate, and the relative intensities of the bands in the individual samples would have to be the same as in the preceding analysis.
Individual samples produced single bands, which had the same mobility, and the size of the DNA fragments on the bands was estimated as 8.0 kb (Fig. 2) . The relative intensities of the bands for the individual samples were roughly equal to those in the preceding analysis (data not shown). These results confirmed our inference, and led to the conclusion that the complete c-myc gene was amplified 5 to 6-fold in OS-4(p4), 2 to 3-fold in OS-4(p20) and 3 to 4-fold in OvCa-1(p9), whereas it was not amplified in the rest of the samples. This was supported by the following observation. In the autoradiogram which was the extensively exposed one of the autoradiogram shown in Fig. 2 , an additional faint bands were present in the individual samples at the same position (not shown). Although the origin of the DNA fragment that corresponds to these faint bands is not known, the intensities of the bands did not differ for the samples, evidence that the amounts of the sample DNAs analyzed were A DNA preparation such as was analyzed as described in Fig.  1 essentially the same. In the OS-4 tumor line, the amount of amplification differed in passages 4 to 20, possibly because of instability of the chromosomes that contain the c-myc gene.
RNAs also were prepared from tumors, HL-60 and normal tissue, and were given Northern blot analysis using the same rat c-myc sequence probe (Fig. 3) . Individual samples gave single bands, which had the same mobility. By comparing the positions of the bands with those of ribosomal RNAs, we estimated the size of the RNAs on these bands as 2.6 kb. This size was approximately the same as that reported for the c-myc transcript of HL-60 (10), confirmation that the RNAs in the samples were transcripts from the c-myc gene.
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These results indicate that the difference in size between the transcripts from the c-myc gene in the tumors and that in normal cells, if any, was not so large as to be distinguishable by the Northern blot hybridization. The intensity of the bands, however, varied in the samples. Densitometry of the bands (data not shown) indicated that the relative amount of the transcript to the total RNA in OS-4(p20) was 6-fold that in normal tissue, and that the relative amounts of the transcript in OCL-1(p42) and OY-1(p40) were the same as in normal tissue.
The experimental data reported here led us to conclude that (1) the c-myc gene was amplified in the human ovarian tumor lines OS-4 and OvCa-1 and (2) the relative amount of the transcript from the c-myc gene compared to the total RNA increased in OS-4. Our conclusions give rise to a suspicion that these alterations may contribute to the genesis of malignant cells in a subset of ovarian tumors.
Some primary malignant cells of other organs have been shown to undergo alteration to their c-myc genes that include the amplification and/or elevated transcription (4, 6, 7, 8, 10) . In contrast, a lymphoma cell line has been shown to undergo the alteration during passage of the cells in vitro (9) . It is, therefore, of interest whether amplification of the c-myc gene in OS-4 and OvCa-1, and the increase in the transcript in OS-4, took place before, or after, transplantation of these tumors to nude mice. If alteration takes place in primary tumors, it would be positive evidence that alteration contributes to the genesis of malignant cells in a subset of ovarian tumors. Although the primary gumors, OS-4 and OvCa-1, are not stocked under conditions suitable for the analysis of DNA, this possibility has yet to be examined using other ovarian tumors.
